Stoke Therapeutics (STOK) Cash from Investing Activities (2018 - 2026)

Stoke Therapeutics' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at $50.7 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 271.88% year-over-year to $50.7 million in Q1 2026; TTM through Mar 2026 was -$149.8 million, a 44.22% decrease from a year earlier, with the FY2025 full-year figure at -$186.8 million, down 73.82% from the prior year.
• Cash from Investing Activities climbed to $50.7 million in Q1 2026 per STOK's latest filing, from -$61.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $67.3 million in Q3 2022 and bottomed at -$148.5 million in Q2 2025.
• The 5-year median for Cash from Investing Activities is $10.0 million (2024), against an average of -$10.8 million.
• Across the five-year window, Cash from Investing Activities slumped 66459.8% in 2022 and jumped 15977.4% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at $22.5 million in 2022, then slumped by 34.32% to $14.8 million in 2023, then tumbled by 94.46% to $819000.0 in 2024, then tumbled by 7555.56% to -$61.1 million in 2025, then surged by 183.02% to $50.7 million in 2026.
• Per Business Quant, the three latest STOK Cash from Investing Activities figures stand at $50.7 million (Q1 2026), -$61.1 million (Q4 2025), and $9.1 million (Q3 2025).